Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: Potential advantages and methodologic pitfalls

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 6, 2014, Pages 794-802

  Demidova, Irina ^a   Barinov, Aleksei ^a   Savelov, Nikita ^b   Gagarin, Ilia ^a   Grinevitch, Viacheslav ^b   Stroiakovaski, Daniil ^b   Popov, Mikhail ^b   Laktionov, Konstantin ^c   Gutorov, Sergei ^d   Smolin, Alexei ^e   Olshanskaya, Yulia ^f   Obukhova, Tatiana ^g  

^a Moscow City Oncology Hospital 62   (Russian Federation)

^b Moscow Oncological Hospital No 62   (Russian Federation)

^c INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^d N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^e Ministry of Defense of the Russian Federation   (Russian Federation)

^f Center for Pediatric Hematology Oncology and Immunology   (Russian Federation)

^g NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; DNA; EML4 ALK FUSION PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ADENOCARCINOMA; ARTICLE; COMPARATIVE STUDY; EVALUATION STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICS;

ADENOCARCINOMA; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; PROSPECTIVE STUDIES; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84902440321     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0762-OA     Document Type: Article

References (34)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(2 1):2129-2139
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500
3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153): 561-566
4. Crystal A, Show A. Variants on a theme: A biomarker of crizotinib response in ALK-positive non-small cell lung cancer? Clin Cancer Res. 2012;18(17):4479-4481
5. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190-1203.
6. Takeuchi K,Choi YL,Togashi Y,et al,KIF5B-ALK, a novel fusion oncokinase ident ified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer,Clin Cancer Res,2009,15,9,3143-3149.
7. Tagashi Y, Soda M, Sakata S, et al. KLC1-ALK: A novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS ONE. 2012; 7(2):e31323
8. Camidge DR, Bang BR, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive nonsmall cell lung cancer (NSCLC). J Clin Oncol. 2011;29(suppl):abstract 2501
9. Sanders H, Li H, Bruey JM, et al. Exon scanning by reverse transcriptasepolymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genetics. 2011;204(1):45-52
10. Shaw AT, Yeap BY, Solomon B J, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 2011;12(11):1004- 1012
11. Camidge DR, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol. 2012;9(5):268-277
12. Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer. 2012;48(7):961-973
13. Garrido P, de Castro J, Coucha A, et al. Guidelines for biomarker testing in advanced non-small-cell lung cancer: A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanis h Society of Pathology (SEAP). Clin Transl Oncol. 2012;14 (5):338-349
14. Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell lung carcinomas of the lung: A review wi th recommendations. Virchows Arch. 2012;461(3):245-257
15. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in nonsmall cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009;174(2): 661-670
16. Bolland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol. 2009;40(8):1152-1158
17. Mino-Kenudson M, Chirieac L, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-re arranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16(5):1561-1571
18. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearr angement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol. 2011;6(3):459-465
19. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identi fied by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;15(9):3143-3149
20. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lympho ma kinase rearrangement by immunohistochemistry in non-small cell lung cancer correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011;6(3): 466-472
21. Inamura K, Takeuchi K, Togashi Y , et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22(4):508-515
22. Park HS, Lee JK, Kim DW, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer. 2012;77(2):288-292
23. Heuckmann JM, Balke -Want H, Malchers F, et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res. 2012;18(17):4682-4690
24. Murakami Y, Mitsudomi T, Yat abe Y. A screening method for the ALK fusion gene in NSCLC. Front Oncol. 2012;2 (24):1-9
25. Crino L, Kim D, Riely G, et al. Initial phase II results with crizotinib in advanced ALK-positi ve non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol. 2011;29(suppl):abstract 7514
26. Shaw A, Yeap B, Solomon B, et al. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. J Clin Oncol. 2011;29(suppl):abstract 7507.
27. US Food Drug Administration,Summary Review,Silver Spring,MD: US Food and Drug Administration,2011. Application, No: 202570 Orig1s000.
28. Just P-A, Cazes A, Audebourg A, et al. Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALKrearrangement in lung cancer: A comprehensive study of Caucasian non-smokers. Lung Cancer. 2011;76(3):309-315.
29. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010; 16(22):5581-5590
30. Wallander M, Geiersbach K, Tripp S, et al.comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma. Arch Pathol Lab Med. 2012;136(7):796-803
31. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010, 46(10):1773-1780
32. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18(5):1472-1482
33. Peled N, Palmer G, Hirsch F, et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thora c Oncol. 2012;7(9):e14-e16
34. Kim RN, Kim A, Choi SH, et al. Novel mechanism of conjoined gene formation in the human genome. Funct Integr Genomics. 2012;12 (1):45-61